Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital

SHANGHAI, April 6, 2021 /PRNewswire/ — Brattea, a leading renal denervation (RDN) medical technology company in China, announced today its successful completion of over $US20 million Series B+ …
( read original story …)

---